Feb. 7, 2013—A team led by Vanderbilt University investigators has discovered two new genes — both coding for the signaling protein calmodulin — associated with severe early-onset disorders of heart rhythm.
Jan. 24, 2013—Vanderbilt University’s Lee Limbird, Ph.D., has received one of pharmacology’s highest honors — the 2013 Julius Axelrod Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET).
Jan. 18, 2013—Understanding how the main receptor for light interacts with other signaling molecules may inform new pharmaceutical development.
Oct. 25, 2012—Heidi Hamm, Ph.D., chair of the Department of Pharmacology, has won the 2012 Ariens Award from the Dutch Pharmacological Society.
Aug. 30, 2012—The spinal cord’s neuropeptide Y signaling pathway may be a good target for new pain therapeutics.
Aug. 28, 2012—A reversible chemical modification of rhodopsin, a receptor for light, plays a role in the degeneration of retinal cells.
Aug. 23, 2012—A new cooperative program between Vanderbilt University and Lipscomb University’s College of Pharmacy is focusing on the next generation of pharmaceutical researchers. By offering a pathway for students to earn both Pharm.D. and Ph.D. degrees, the program aims to boost the number of pharmacy-trained research scientists.
Aug. 10, 2012—Females may be at higher risk of potentially fatal heart condition due to gender differences in a protein involved in the heart’s electrical activity.
Jul. 31, 2012—A combination of biomarkers may reveal new clues about causes of and potential interventions for autism.
Jul. 24, 2012—Creating a device out of human cells that simulates brain chemistry is the goal of a $6.4 million grant which is part of major new federal initiative to develop a series of “organs on a chip” designed to improve the drug development process.
Jul. 18, 2012—Stress can promote breast cancer cell colonization of bone, Vanderbilt Center for Bone Biology investigators have discovered.
Jul. 17, 2012—When discovering drugs for brain disorders, it’s important to test the candidates in multiple ways to avoid advancing those with restricted physiological effects.